Centessa Pharmaceuticals (CNTA) Cash from Investing Activities (2022 - 2025)
Centessa Pharmaceuticals (CNTA) has disclosed Cash from Investing Activities for 4 consecutive years, with -$218.1 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities fell 972.54% to -$218.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$418.5 million through Dec 2025, down 1438.57% year-over-year, with the annual reading at -$418.5 million for FY2025, 1438.57% down from the prior year.
- Cash from Investing Activities for Q4 2025 was -$218.1 million at Centessa Pharmaceuticals, down from $61.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $61.9 million in Q3 2025, with the low at -$222.4 million in Q1 2025.
- Average Cash from Investing Activities over 4 years is -$32.2 million, with a median of -$343000.0 recorded in 2022.
- Peak annual rise in Cash from Investing Activities hit 304512.5% in 2023, while the deepest fall reached 35873.33% in 2023.
- Over 4 years, Cash from Investing Activities stood at -$446000.0 in 2022, then crashed by 3997.53% to -$18.3 million in 2023, then soared by 236.8% to $25.0 million in 2024, then crashed by 972.54% to -$218.1 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$218.1 million, $61.9 million, and -$40.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.